Johnson & Johnson announced positive Phase 2b COPERNICUS study results showing low rates of rash, blood clots, and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE in treating advanced non-small cell lung cancer with EGFR mutations. The study involved 214 diverse patients and demonstrated fewer than 1% treatment discontinuations due to related adverse events at one year, improving on previous intravenous treatment data. These findings support RYBREVANT FASPRO plus LAZCLUZE as a first-line treatment option with a better patient experience through less frequent dosing and prophylactic care. The study reflects Johnson & Johnson's commitment to advancing cancer treatment delivery and management in real-world settings.
Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a...
Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Five dividend stocks—Procter & Gamble, Johnson & Johnson, Coca-Cola, Colgate-Palmolive, and PepsiCo—have consistently raised their dividends through every U.S. recession since at least 1963. These companies demonstrated resilience during major downtu...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
